Effectiveness and tolerability of fixed-dose combination enalapril plus nitrendipine in hypertensive patients: Results of the 3-month observational, post-marketing, multicentre, prospective CENIT study

Clinical Drug Investigation

Volumn 29, Issue 7, 2009, Pages 459-469

  Sierra, Alejandro De La ^a   Roca Cusachs, Alejandro ^b   Redón, Josep ^c   Marín, Rafael ^d   Luque, Manuel ^e   Figuera, Mariano De La ^f   Garcia Garcia, Margarida ^g   Falkon, Liliana ^h  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f La Mina Health Centre   (Spain)

^g Operations Department   (Spain)

^h I3 Research   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; NITRENDIPINE;

ABDOMINAL PAIN; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; COUGHING; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DYSLIPIDEMIA; EDEMA; ESSENTIAL HYPERTENSION; FACE ERYTHEMA; FEMALE; FLUSHING; FOLLOW UP; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBESITY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; POSTMARKETING SURVEILLANCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; REST; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; SITTING; SPAIN; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; TACHYCARDIA; TREATMENT RESPONSE; VERTIGO;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ENALAPRIL; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NITRENDIPINE; PRIMARY HEALTH CARE; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES;

EID: 67650281464     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/00044011-200929070-00004     Document Type: Article

References (36)

1. Tamargo J. Asociación de nitrendipino y enalapril: nuevas estrategias en el tratamiento de la hipertensión arterial. Drugs Today 2001; 37 Suppl.: 1-53
2. Lewington S, Clarke R, Qizilbash N, et al., Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13
3. Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371: 1513-8
4. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC2007). Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105-87
5. Weir MR. When antihypertensive monotherapy fails: fixeddose combination therapy. South Med J 2000; 93: 548-56
6. -1999 World Health Organization - International Society of Hypertension. Guidelines for the management of hypertension. Guidelines Subcommittee. J Hypertens 1999; 17: 151-85
7. Bangalore S, Shahane A, Parkar S, et al. Compliance and fixed-dose combination therapy. Curr Hypertens Rep 2007; 9: 184-9
8. Ferran M, Parcet J, Casabella B, et al. Educación sanitaria a pacientes hipertensos: propuesta de un test de conocimiento y cumplimiento. Aten Primaria 1998; 5: 25-30
9. Weir MR. When antihypertensive monotherapy fails: fixeddose combination therapy. South Med J. 2000; 93: 548-56
10. McInnes GT. Antihypertensive drugs in combination: additive or greater than additive? J Hum Hypertens 2007; 21: 914-6
11. Smith DH. Fixed-dose combination antihypertensives and reduction in target organ damage: are they all the same? Am J Cardiovasc Drugs 2007; 7: 413-22
12. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: metaanalysis on 11,000 participants from 42 trials. Am J Med 2009; 122: 290-300
13. Neutel JM. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. Curr Med Res Opin 2008; 24 (8): 2389-401
14. Weir MR, Levy D, Crikelair N, et al. Time to achieve bloodpressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am J Hypertens 2007; 20: 807-15
15. Siddiqui MA, Plosker GL. Fixed-dose combination enalapril/ nitrendipine: a review of its use in mild-to-moderate hypertension. Drugs 2004; 64: 1135-48
16. Meurin P. The ASCOT trial: clarifying the role of ACE inhibition in the reduction of cardiovascular events in patients with hypertension. Am J Cardiovasc Drugs 2006; 6: 327-34
17. Roca-Cusachs A, Torres F, Horas M, et al. Nitrendipine and enalapril combination therapy in mild to moderate hypertension: assessment of dose-response relationship by a clinical trial of factorial design. J Cardiovasc Pharmacol 2001; 38: 840-9
18. Gradman AH, Cutler NR, Davis PJ, et al. Combined enalapril and felodipine extended release (ER) for systemic hypertension. Enalapril-Felodipine ER Factorial Study Group. Am J Cardiol 1997; 79: 431-5
19. Cushman WC, Cohen JD, Jones RP, et al. Comparison of fixed combination of enalapril/diltiazam ER and their monotherapies in stage 1 to 3 essential hypertension. Am J Hypertens 1998; 11: 23-30
20. King P, Peacock I, Donnelly R. The UK prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol 1999; 48: 643-8
21. Neutel JM. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. Curr Med Res Opin 2008; 24: 2389-401
22. Staessen JA, Fagard R, Thijs L, et al. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-64
23. Rigaud AS, Seux ML, Staessen JA, et al. Cerebral complications of hypertension. J Hum Hypertens 2000; 14: 605-16
24. Thijs L, Staessen JA, Beleva S, et al. How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2). Curr Control Trials Cardiovasc Med 2001; 18 (2): 298-306
25. Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162: 2046-52
26. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-28
27. Machin D, Campbell M, Fayers P, et al. Sample size tables for clinical studies. 2nd edition. Oxford: Blackwell Scientific Publications, 1997
28. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Institutes of Health. National Heart, Lung, and Blood Institute. National High Blood Pressure Education Program. NIH Publication 1997. Arch Intern Med 1997; 157: 2413-46
29. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67-74
30. Val A, Amorós G, Martínez P, et al. Descriptive study of patient compliance in pharmacologic antihypertensive treatment and validation of the Morisky and Green test. Aten Primaria 1992; 10: 767-70
31. The WHO. Adverse Reaction Terminology - WHO-ART. Terminology for coding clinical information in relation to drug therapy. Uppsala (Sweden): The Uppsala Monitoring Centre, 1999
32. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363-9
33. Marín-Iranzo R, dela Sierra-Iserte A,Roca-Cusachs A,et al., grupo del estudio ENVIDA. Double blind study of the efficacy and safety of the fixed dose combination of enalapril 10 mg/nitrendipine 20 mg versus the increase of amlopidine dose in essential hypertensive patients not controlled with amlodipine 5 mg. Rev Clin Esp 2005; 205: 418-24
34. Rubio-Guerra AF, Treviño-Gomezharper C, RodríguezLó pez L, et al. Renoprotective effects of the combination trandolapril/verapamil in patients with type 2 diabetes mellitus and hypertension. Clinical Drug Invest 2002; 22: 541-6
35. Bakris G, Molitch M, Hewkin A, et al., STAR Investigators. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592-7
36. Bulpitt CJ, Beckett NS, Fletcher AE, et al. Withdrawal from treatment in the Syst-Eur Trial. J Hypertens 2002; 20: 339-46